Sugi Predict

Sugi Predict / Compounds / SCHEMBL4597943

SCHEMBL4597943

SCHEMBL4597943

C=C(C(=O)Nc1cc2c(N)ncnc2cc1OCCCN1CCOCC1)c1ccc(F)c(Cl)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 19/20 0.66
▸ ERBB2 P04626 4/20 0.61
▸ ERBB4 Q15303 3/20 0.61
▸ KIT P10721 2/20 0.61
▸ SRC P12931 2/20 0.61
▸ ERBB3 P21860 2/20 0.61
▸ BMPR1B O00238 1/20 0.61
▸ CIT O14578 1/20 0.61
▸ MAP2K7 O14733 1/20 0.61
▸ GAK O14976 1/20 0.61
▸ EPHB6 O15197 1/20 0.61
▸ MAP3K7 O43318 1/20 0.61
▸ RIPK2 O43353 1/20 0.61
▸ STK17B O94768 1/20 0.61
▸ STK10 O94804 1/20 0.61
▸ ABL1 P00519 1/20 0.61
▸ LCK P06239 1/20 0.61
▸ FYN P06241 1/20 0.61
▸ YES1 P07947 1/20 0.61
▸ LYN P07948 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15876946 0.80 EGFR (0.88) EGFRERBB2ERBB4KITSRC
SCHEMBL15876866 0.80 EGFR (0.88) EGFRERBB2ERBB4KITSRC
SCHEMBL28643088 0.80 EGFR (1.00) EGFRERBB2ERBB4KITSRC
SCHEMBL672223 0.79 EGFR (0.62) EGFRERBB2ERBB4KITSRC
SCHEMBL2224110 0.77 EGFR (0.66) EGFRERBB2ERBB4KITSRC
SCHEMBL30579743 0.77 EGFR (0.66) EGFRERBB2ERBB4KITSRC
SCHEMBL14671667 0.77 EGFR (0.82) EGFRERBB2ERBB4KITSRC
SCHEMBL15877026 0.77 EGFR (0.70) EGFRERBB2ERBB4KITSRC
SCHEMBL15877380 0.77 EGFR (0.70) EGFRERBB2ERBB4KITSRC
SCHEMBL14264600 0.76 EGFR (0.89) EGFRERBB2ERBB4KITSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099594-A1 THERAPEUTIC BIFUNCTIONAL AGENTS INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2026-05-15 — — WO disclosed
WO-2024052693-A1 PRODRUGS CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 — — WO disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 — — WO disclosed
US-11530193-B2 Kinase inhibitors THE UNIVERSITY OF MANCHESTER (GB) 2022-12-20 — — US disclosed
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2021-07-29 — — US disclosed
EP-3523295-A1 DEUTERATED N-(5-(2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDO)-2-FLUOROPHENYL)-2-((4-ETHYLPIPERAZIN-1 -YL)METHYL)QUINOLINE-6-CARBOXAMIDE Cancer Research Technology Limited (GB) 2019-08-14 — — EP disclosed
EP-3394055-A1 NOVEL PYRROLO[3,2-c]PYRIDINE-6-AMINO DERIVATIVES Cancer Research Technology Limited (GB) 2018-10-31 — — EP disclosed
EP-3334443-A1 COMPOSITIONS Sigmoid Pharma Limited (IE) 2018-06-20 — — EP disclosed
WO-2018065787-A1 DEUTERATED N-(5-(2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDO)-2-FLUOROPHENYL)-2-((4-ETHYLPIPERAZIN-1 -YL)METHYL)QUINOLINE-6-CARBOXAMIDE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-04-12 — — WO disclosed
EP-3283484-A1 QUINOLINE DERIVATIVES AS INHIBITORS OF HEAT SHOCK FACTOR 1 PATHWAY ACTIVITY CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-02-21 — — EP disclosed
WO-2014191736-A1 HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS REDX PHARMA LIMITED (GB) 2014-12-04 — — WO disclosed
WO-2014191737-A1 HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS REDX PHARMA LIMITED (GB) 2014-12-04 — — WO disclosed
WO-2014162123-A1 THERAPEUTIC USES OF BISPHOSPHONATES THE UNIVERSITY OF SHEFFIELD (GB) 2014-10-09 — — WO disclosed
WO-2014162124-A1 THERAPEUTIC USES OF BISPHOSPHONATES THE UNIVERSITY OF SHEFFIELD (GB) 2014-10-09 — — WO disclosed
WO-2014037750-A1 INHIBITOR COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-03-13 — — WO disclosed
WO-2013190320-A1 IMIDAZOPYRIDINES AS INHIBITORS OF AURORA KINASE AND/OR FLT3 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-12-27 — — WO disclosed
WO-2013190319-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-12-27 — — WO disclosed
WO-2013156780-A1 THERAPEUTIC COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2013-10-24 — — WO disclosed
EP-1877397-A1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF EGF AND/OR ERBB2 RECEPTOR TYROSINE KINASE AstraZeneca AB (SE) 2008-01-16 — — EP disclosed
WO-2006117521-A1 QUINAZOLINE DERIVATIVES AS INHIBITORS OF EGF AND/OR ERBB2 RECEPTOR TYROSINE KINASE ASTRAZENECA AB (SE) 2006-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530193-B2 Kinase inhibitors CAMKK2, CAMK1, CAMKK1 EGFR 1338/4885ERBB2 191/4885ERBB4 677/4885
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NISCH, ABL1, PAICS EGFR 3439/4885ERBB2 902/4885ERBB4 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.